Identification of immune-based prostate cancer subtypes using mRNA expression

Song, Jukun; He, Song; Wang, Wei; Su, Jiaming; Yuan, Dongbo; Chen, Weihong; Zhu, Jianguo

doi:10.21203/rs.2.23038/v1

2020

DOI: 10.21203/rs.2.23038/v1

|View full text |Cite

Preprint

Identification of immune-based prostate cancer subtypes using mRNA expression

Jukun Song

Song He

Wei Wang

et al.

Abstract: Background

Help me understand this report

View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

References 39 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway

et al. 2020

Self Cite

View full text Add to dashboard Cite

The HIF-1 signaling pathway plays an important role in the pathogenesis of cancer. Many studies have explored the progression of prostate cancer (PCa) under hypoxic conditions based on transcriptome data; few have uncovered the immunogenomic profiling and prostate cancer classification based on the HIF-1 signaling pathway. This pathway may help to identify the optimal subset of PCa patients responsive to immunotherapy/chemotherapy. The immunogenomic PCa subsets were classified based on profiling of the HIF-1 signaling pathway, using four publicly available PCa datasets. Three PCa subtypes that named as HIF-1 High (HIF-1_H), HIF-1 Medium (HIF-1_M), and HIF-1 Low (HIF-1_L) were identified. Functional enrichment was analyzed in each subtype. Several cancer-associated and immune-related pathways were hyperactivated in the HIF-1_H subtypes. In contrast, HIF-1_L subtypes were enriched in cell cycle and cell repair. Compared with other subtypes, HIF-1_H subtypes have greater immune cell infiltration, anti-tumor immune activity, and better survival prognosis. The submap and TIDE algorithm were used to predict the clinical response to immune checkpoint blockade, and GDSC was employed to screen potential chemotherapeutic targets for the treatment of PCa. Several chemotherapy drugs were identified in the GDSC dataset, including ABT 888, Temsirolimus, and EHT 1864. Meanwhile, HIF-1_H was defined as an early PCa marker, which is more likely to respond to immunotherapy. The identification of immunogenomic PCa subtypes based on the HIF-1 signaling pathway has potential clinical implications for PCa treatment. Immunopositive PCa subtypes will help to explore the reasons for the poor response of PCa to immunotherapy, and it is expected that immunotherapy will guide the personalized treatment of PCa patients.

show abstract

Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Identification of immune-based prostate cancer subtypes using mRNA expression

Abstract: Background

Cited by 1 publication

References 39 publications

Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway

Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway

Contact Info

Product

Resources

About